Emergent BioSolutions signs agreement for large scale coronavirus vaccine substance manufacturingChristian Fernsby ▼ | July 6, 2020
Emergent BioSolutions announced a five year manufacturing services agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson and Johnson, for large scale drug substance manufacturing for Johnson and Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology.
Substance Emergent BioSolutions
Topics: Emergent BioSolutions
Under the agreement, Emergent will begin providing large scale drug substance manufacturing for Johnson and Johnson’s adenovirus-based coronavirus vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement.
For the subsequent years beginning 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually. ■